Payment overview · 2025
General Payments
$317.26
13 reported records · 8 companies
Healthcare provider profile · identity verified
Mark Norton, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LAUREL, MS · NPI 1881608495
Verified facts
What the public records show
CMS Open Payments records show Mark Norton, M.D. received $317.26 in general payments during 2025 across 13 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 29.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Ozempic, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rexulti by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $92.57 | 29.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $79.27 | 25.0% | 4 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $34.80 | 11.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.17 | 9.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.32 | 7.7% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.15 | 6.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.81 | 5.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.17 | 5.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $317.26 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $92.57 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $42.37 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $34.80 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $30.17 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $24.32 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 115 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 68 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 127 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 105 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
116 | 30 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
115 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
127 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
105 | 20 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
68 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 854 | 199 |
| Levothyroxine Sodium | Levothyroxine Sodium | 741 | 128 |
| Atorvastatin Calcium | Atorvastatin Calcium | 676 | 142 |
| Gabapentin | Gabapentin | 619 | 110 |
| Omeprazole | Omeprazole | 565 | 129 |
| Losartan Potassium | Losartan Potassium | 563 | 118 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 530 | 103 |
| Potassium Chloride | Potassium Chloride | 516 | 116 |
| Pantoprazole Sodium | Pantoprazole Sodium | 490 | 119 |
| Furosemide | Furosemide | 487 | 128 |
| Jantoven | Warfarin Sodium | 458 | 12 |
| Metformin Hcl | Metformin Hcl | 381 | 82 |
| Famotidine | Famotidine | 313 | 63 |
| Meloxicam | Meloxicam | 304 | 62 |
| Trazodone Hcl | Trazodone Hcl | 293 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 287 | 67 |
| Eliquis | Apixaban | 253 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 251 | 50 |
| Simvastatin | Simvastatin | 248 | 52 |
| Lisinopril | Lisinopril | 239 | 57 |
| Sertraline Hcl | Sertraline Hcl | 231 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 225 | 52 |
| Donepezil Hcl | Donepezil Hcl | 221 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 221 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 221 | 48 |
| Montelukast Sodium | Montelukast Sodium | 208 | 44 |
| Carvedilol | Carvedilol | 205 | 59 |
| Clopidogrel | Clopidogrel Bisulfate | 205 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 205 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 200 | 41 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 195 | 51 |
| Buspirone Hcl | Buspirone Hcl | 193 | 33 |
| Tramadol Hcl | Tramadol Hcl | 181 | 56 |
| Azithromycin | Azithromycin | 170 | 124 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 168 | 33 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 167 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 164 | 27 |
| Memantine Hcl | Memantine Hcl | 161 | 34 |
| Spironolactone | Spironolactone | 156 | 36 |
| Allopurinol | Allopurinol | 155 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 153 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 151 | 39 |
| Ropinirole Hcl | Ropinirole Hcl | 141 | 28 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 140 | 31 |
| Glimepiride | Glimepiride | 139 | 33 |
| Mirtazapine | Mirtazapine | 134 | 25 |
| Cephalexin | Cephalexin | 129 | 92 |
| Jardiance | Empagliflozin | 127 | 23 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 125 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 120 | 40 |
| Ondansetron Hcl | Ondansetron Hcl | 119 | 64 |
| Tizanidine Hcl | Tizanidine Hcl | 117 | 21 |
| Linzess | Linaclotide | 116 | 30 |
| Farxiga | Dapagliflozin Propanediol | 115 | 13 |
| Alprazolam | Alprazolam | 113 | 15 |
| Myrbetriq | Mirabegron | 113 | 16 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 112 | 21 |
| Cefdinir | Cefdinir | 108 | 87 |
| Nystop | Nystatin | 107 | 38 |
| Ozempic | Semaglutide | 105 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 104 | 23 |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 103 | 66 |
| Albuterol Sulfate | Albuterol Sulfate | 102 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 96 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 92 | 17 |
| Levetiracetam | Levetiracetam | 91 | 22 |
| Estradiol | Estradiol | 86 | 17 |
| Megestrol Acetate | Megestrol Acetate | 86 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 85 | 27 |
| Paroxetine Hcl | Paroxetine Hcl | 85 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 84 | 14 |
| Pregabalin | Pregabalin | 83 | 20 |
| Ondansetron Odt | Ondansetron | 80 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 79 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 76 | 15 |
| Ezetimibe | Ezetimibe | 76 | 18 |
| Novolog | Insulin Aspart | 76 | 18 |
| Sucralfate | Sucralfate | 76 | 18 |
| Fluconazole | Fluconazole | 75 | 45 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 72 | 15 |
| Metformin Hcl Er | Metformin Hcl | 70 | 16 |
| Promethazine Hcl | Promethazine Hcl | 69 | 16 |
| Gemtesa | Vibegron | 68 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 66 | 19 |
| Ibuprofen | Ibuprofen | 64 | 19 |
| Valsartan | Valsartan | 64 | 16 |
| Levofloxacin | Levofloxacin | 63 | 52 |
| Glipizide | Glipizide | 61 | suppressed |
| Lorazepam | Lorazepam | 61 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 18 |
| Nebivolol Hcl | Nebivolol Hcl | 59 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 58 | suppressed |
| Synthroid | Levothyroxine Sodium | 58 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 57 | suppressed |
| Nifedipine Er | Nifedipine | 57 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 56 | 11 |
| Finasteride | Finasteride | 55 | 11 |
| Januvia | Sitagliptin Phosphate | 55 | suppressed |
| Loperamide | Loperamide Hcl | 55 | 37 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 54 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | suppressed |
| Humalog | Insulin Lispro | 50 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | 18 |
| Movantik | Naloxegol Oxalate | 50 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 27 |
| Baclofen | Baclofen | 48 | 12 |
| Clonidine Hcl | Clonidine Hcl | 47 | 13 |
| Fentanyl | Fentanyl | 45 | suppressed |
| Glipizide Er | Glipizide | 45 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 45 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Fenofibrate | Fenofibrate | 44 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 44 | 14 |
| Methylprednisolone | Methylprednisolone | 44 | 33 |
| Midodrine Hcl | Midodrine Hcl | 44 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 43 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 43 | suppressed |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Clonazepam | Clonazepam | 42 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 42 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 41 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 18 |
| Meclizine Hcl | Meclizine Hcl | 40 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 38 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | suppressed |
| Prednisone | Prednisone | 38 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 23 |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Primidone | Primidone | 37 | suppressed |
| Atenolol | Atenolol | 36 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 36 | suppressed |
| Irbesartan | Irbesartan | 36 | suppressed |
| Topiramate | Topiramate | 36 | suppressed |
| Xifaxan | Rifaximin | 36 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | suppressed |
| Celecoxib | Celecoxib | 35 | suppressed |
| Ranolazine Er | Ranolazine | 32 | suppressed |
| Rexulti | Brexpiprazole | 32 | suppressed |
| Acyclovir | Acyclovir | 31 | suppressed |
| Colchicine | Colchicine | 31 | 12 |
| Lacosamide | Lacosamide | 31 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 30 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 30 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | suppressed |
| Lactulose | Lactulose | 29 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 24 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 28 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 28 | suppressed |
| Latanoprost | Latanoprost | 28 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 28 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | 11 |
| Pilocarpine Hcl | Pilocarpine Hcl | 27 | suppressed |
| Carisoprodol | Carisoprodol | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 26 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Nystatin | Nystatin | 25 | 19 |
| Diltiazem Hcl | Diltiazem Hcl | 23 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| Admelog | Insulin Lispro | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 22 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Eplerenone | Eplerenone | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | 17 |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Kerendia | Finerenone | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Insulin Lispro | Insulin Lispro | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 15 |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Levemir | Insulin Detemir | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | 13 |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Famciclovir | Famciclovir | 13 | 13 |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 13 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $317.26 · 13 records | Otsuka America Pharmaceutical, Inc. | FARXIGA, GEMTESA, INSPIRE, JARDIANCE, Ozempic, QULIPTA, REXULTI, Rybelsus, UBRELVY, ZENPEP | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error